Biofrontera (Biofrontera) Retained Earnings : $-110.09 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biofrontera Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biofrontera's retained earnings for the quarter that ended in Mar. 2024 was $-110.09 Mil.

Biofrontera's quarterly retained earnings increased from Sep. 2023 ($-103.18 Mil) to Dec. 2023 ($-99.65 Mil) but then declined from Dec. 2023 ($-99.65 Mil) to Mar. 2024 ($-110.09 Mil).

Biofrontera's annual retained earnings declined from Dec. 2021 ($-78.88 Mil) to Dec. 2022 ($-79.52 Mil) and declined from Dec. 2022 ($-79.52 Mil) to Dec. 2023 ($-99.65 Mil).

Biofrontera Retained Earnings Historical Data

The historical data trend for Biofrontera's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera Retained Earnings Chart

Biofrontera Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

-30.18

-41.17

-78.88

-79.52

-99.65

Biofrontera Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial												-87.00	-96.83	-103.18	-99.65	-110.09

Biofrontera Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Biofrontera (NAS:BFRI) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Biofrontera (Biofrontera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Presidential Way, Suite 330, Woburn, MA, USA, 01801

Website

https://www.biofrontera-us.com

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Executives

Heikki Lanckriet	director	C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler	officer: Chief Financial Officer	84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber	director	119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii	director	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman	director	5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge	director	21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera	10 percent owner	HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates	officer: Controller	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco	director, officer: Chief Financial Officer/COO	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert	director, officer: Chief Executive Officer	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801